

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No.: 02-326-A (400.046US))

In the Application of:)
James McSwiggen)
Serial No.: To be assigned)
Filed: Herewith)
For: Nucleic Acid Treatment of Diseases)
Or Conditions Related to Levels of)
RAS, HER2, and HIV)
)
)
)
)
)

) Examiner: TBA
)
)
)
)
)
)

) Art Group: TBA
)
)
)
)

) Confirmation No.: TBA
)
)

Mail Stop New Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. § 1.821(f)

Sir/Madam:


The undersigned representative hereby declares that the content of the electronic copies of the Sequence Listing, submitted in the above-identified application in compliance with 37 C.F.R. § 1.52(e) on Compact Disc-Recordable (CD-R) medium in duplicate (COPY 1 and COPY 2), in lieu of the paper copy under 37 C.F.R. § 1.821(c), and computer readable form copy of the Sequence Listing, submitted in the above-identified application in accordance with 37 C.F.R. § 1.821(e), are identical in content. The sequence listing submitted herewith does not extend beyond the scope of the specification, and thus, does not contain new matter. The CD-R labeled "CRF of Sequence Listing submitted under 37 C.F.R. § 1.821(e)" contains an IBM compatible dos-text file of the sequence listing named "02-326-A.SeqListing".

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

Dated: November 26, 2003

By:



Andrew W. Williams
Reg. No. 48,644